Aduro BioTech Inc (NASDAQ:ADRO) CFO Jennifer Lew sold 5,623 shares of the company’s stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $6.50, for a total transaction of $36,549.50. Following the sale, the chief financial officer now directly owns 141,813 shares of the company’s stock, valued at approximately $921,784.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
NASDAQ:ADRO traded up $0.28 on Friday, reaching $6.75. 257,329 shares of the stock traded hands, compared to its average volume of 282,302. The company has a market capitalization of $549.47 million, a PE ratio of -4.75 and a beta of 2.23. Aduro BioTech Inc has a 1-year low of $5.10 and a 1-year high of $11.55.
Aduro BioTech (NASDAQ:ADRO) last released its earnings results on Wednesday, August 1st. The biotechnology company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.02. The business had revenue of $2.64 million during the quarter, compared to the consensus estimate of $3.74 million. Aduro BioTech had a negative net margin of 574.11% and a negative return on equity of 44.97%. research analysts expect that Aduro BioTech Inc will post -1.25 EPS for the current fiscal year.
ADRO has been the subject of several recent analyst reports. Canaccord Genuity reaffirmed a “buy” rating and set a $30.00 price objective on shares of Aduro BioTech in a research report on Thursday, August 2nd. HC Wainwright set a $10.00 price objective on shares of Aduro BioTech and gave the stock a “buy” rating in a research report on Thursday, August 2nd. BidaskClub raised shares of Aduro BioTech from a “hold” rating to a “buy” rating in a research report on Monday, June 18th. Zacks Investment Research raised shares of Aduro BioTech from a “hold” rating to a “buy” rating and set a $8.00 target price for the company in a report on Tuesday, July 3rd. Finally, ValuEngine raised shares of Aduro BioTech from a “strong sell” rating to a “sell” rating in a report on Thursday, August 30th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $13.67.
A number of large investors have recently added to or reduced their stakes in ADRO. Capital Fund Management S.A. acquired a new stake in Aduro BioTech during the 2nd quarter valued at approximately $130,000. Sofinnova Ventures Inc acquired a new stake in Aduro BioTech during the 1st quarter valued at approximately $155,000. Legal & General Group Plc increased its position in Aduro BioTech by 105.3% during the 1st quarter. Legal & General Group Plc now owns 22,233 shares of the biotechnology company’s stock valued at $206,000 after purchasing an additional 11,405 shares during the period. MetLife Investment Advisors LLC increased its position in Aduro BioTech by 70.6% during the 2nd quarter. MetLife Investment Advisors LLC now owns 31,799 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 13,156 shares during the period. Finally, Quantitative Systematic Strategies LLC acquired a new stake in Aduro BioTech during the 1st quarter valued at approximately $238,000. 49.01% of the stock is owned by institutional investors and hedge funds.
Aduro BioTech Company Profile
Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.
Recommended Story: New Google Finance Tool and Screening Stocks
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.